NextCure reports FY2022 net loss of $74.7M; cash $159.9M, runway into mid-2025

NextCure, Inc.

Net loss of $74.7M for FY2022 vs $69.4M in FY2021, driven by higher R&D expenses.
Cash, equivalents, and marketable securities $159.9M at Dec 31, 2022, down from $219.6M.
R&D expenses $54.2M (FY2022) vs $50.2M (FY2021); G&A $21.7M vs $20.6M.
NC410 Phase 1b/2 combo with pembrolizumab update expected mid-2023; NC762 update Q4 2023.
NC525 dosed first patient in Phase 1 AML trial Feb 2023; initial data expected Q4 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.